Drugs / Elesclomol
Elesclomol
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01280786 | Jan 2011 → Jun 2014 | acute myeloid leukemia | Synta Pharmaceuticals Corp. | Unknown | No outcome recorded |
| Phase 1 | NCT00827203 | Jan 2009 → Jan 2011 | metastatic neoplasm | Synta Pharmaceuticals Corp. | Suspended | No outcome recorded |
| Phase 1 | NCT00808418 | Nov 2008 → May 2010 | prostate cancer | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 1 | NCT00088114 | Jan 2003 → Oct 2004 | neoplasm | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00084214 | May 2004 → ? | melanoma | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 1/2 | NCT00088088 | Mar 2004 → Mar 2005 | non-small cell lung carcinoma | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00888615 | Dec 2010 → Sep 2011 | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +10 | GOG Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00087997 | Jul 2004 → Oct 2005 | soft tissue sarcoma | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00522834 Comparator | Aug 2007 → Jun 2009 | melanoma | Synta Pharmaceuticals Corp. | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elesclomol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00827203 ↗ |
| Known as | Elesclomol Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00888615 ↗ |
| Known as | GSK-842879 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1972860 ↗ |
| Known as | GSK-842879A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1972860 ↗ |
| Known as | STA-4783 | “Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure.” NCT00522834 ↗ |
| Modality | Small molecule | — CHEMBL1972860 ↗ |
| Route | Intravenous | “213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle.” NCT00522834 ↗ |